Comparison of the efficacy and safety of three vasoactive agents-dopamine, norepinephrine, and epinephrine-in the treatment of patients with pulmonary hypertension crisis: prospective, randomised controlled trial monitored by haemodynamic monitoring

Inclusion Criteria:

1. Age > 18 years old;
2. Signed informed consent form;
3. Confirmed diagnosis of arterial pulmonary hypertension (PAH) and/or chronic thromboembolic pulmonary hypertension (CTEPH);
4. Presenting with manifestations of pulmonary hypertensive crisis;
5. Receiving both diagnosis and treatment in-hospital;
6. No intravenous administration of the vasopressor drugs (including dopamine, norepinephrine, and epinephrine) under study at enrollment.

Exclusion Criteria:

1. At SCAI stage D or stage E ;
2. Patients who only receive a diagnosis but no treatment in the hospital;
3. Uncontrolled hyperthyroidism;
4. Complicated with angle-closure glaucoma;
5. Hypersensitivity to the study drug;
6. Ongoing use of halogenated hydrocarbon general anesthetics such as cyclopropane and halothane;
7. Ongoing use of monoamine oxidase inhibitor (MAOI) antidepressants or anti-Parkinson drugs (phenelzine, tranylcypromine, isocarboxazid, moclobemide);
8. Pregnancy;
9. Already receiving the vasopressor drugs (dopamine, norepinephrine, epinephrine) under study at enrollment.